Suven Life Sciences secures 4 product patents for NCE

18 Aug 2011 Evaluate

Suven Life Sciences has secured grant of four product patents, one from Europe, two from New Sri Lanka and one from Korea corresponding to the New Chemical Entities (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these patents are valid through 2027, 2025 and 2024 respectively.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD) , Huntingon’s disease, Parkinson and Schizophrenia.

With these patents, Suven has a total of eleven granted patents from Europe, eight granted patents from Sri Lanka, five granted patents from Korea for the NCEs. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.

Suven Life Science focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has six internally-discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease.

Suven Life Sciences Share Price

170.15 -1.25 (-0.73%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×